The Future of Lymphedema: Potential Therapeutic Targets for Treatment

Dayan JH, Ly CL, Kataru RP, Mehrara BJ. Lymphedema: pathogenesis and novel therapies. Annu Rev Med. 2018;69:263–76. https://doi.org/10.1146/annurev-med-060116-022900.

Article  CAS  PubMed  Google Scholar 

Greene AK, Goss JA. Diagnosis and staging of lymphedema. Semin Plast Surg. 2018;32(1):12–6. https://doi.org/10.1055/s-0038-1635117.

Article  PubMed  PubMed Central  Google Scholar 

Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147–54. https://doi.org/10.1196/annals.1413.014.

Article  PubMed  Google Scholar 

DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15. https://doi.org/10.1016/s1470-2045(13)70076-7.

Article  PubMed  Google Scholar 

Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg. 2007;59(4):464–72. https://doi.org/10.1097/01.sap.0000257149.42922.7e.

Article  CAS  PubMed  Google Scholar 

Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 2018;379(20):1937–44. https://doi.org/10.1056/NEJMcp1803290.

Article  PubMed  Google Scholar 

Salinas-Huertas S, Luzardo-González A, Vázquez-Gallego S, et al. Risk factors for lymphedema after breast surgery: a prospective cohort study in the era of sentinel lymph node biopsy. Breast Dis. 2021. https://doi.org/10.3233/bd-210043.

Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116(22):5138–49. https://doi.org/10.1002/cncr.25458.

Article  PubMed  Google Scholar 

Beaulac SM, McNair LA, Scott TE, LaMorte WW, Kavanah MT. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg. 2002;137(11):1253–7. https://doi.org/10.1001/archsurg.137.11.1253.

Article  PubMed  Google Scholar 

Heiney SP, McWayne J, Cunningham JE, et al. Quality of life and lymphedema following breast cancer. Lymphology. 2007;40(4):177–84.

CAS  PubMed  Google Scholar 

Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013;7(1):83–92. https://doi.org/10.1007/s11764-012-0247-5.

Article  PubMed  Google Scholar 

Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27(12):2007–14. https://doi.org/10.1200/JCO.2008.18.3517.

Article  PubMed  Google Scholar 

Taghian NR, Miller CL, Jammallo LS, O’Toole J, Skolny MN. Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol. 2014;92(3):227–34. https://doi.org/10.1016/j.critrevonc.2014.06.004.

Article  PubMed  Google Scholar 

Yuan Y, Arcucci V, Levy SM, Achen MG. Modulation of immunity by lymphatic dysfunction in lymphedema. Front Immunol. 2019;10:76. https://doi.org/10.3389/fimmu.2019.00076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armer J, Porock D. Self-management of fatigue among women with lymphedema. Lymphology. 2002;35(Suppl):208–13.

Google Scholar 

De Vrieze T, Nevelsteen I, Thomis S, et al. What are the economic burden and costs associated with the treatment of breast cancer-related lymphoedema? A systematic review. Support Care Cancer. 2020;28(2):439–49. https://doi.org/10.1007/s00520-019-05101-8.

Article  PubMed  Google Scholar 

Barufi S, Pereira de Godoy HJ, Pereira de Godoy JM, Guerreiro Godoy MF. Exercising and compression mechanism in the treatment of lymphedema. Cureus. 2021;13(7):e16121. https://doi.org/10.7759/cureus.16121.

Article  PubMed  PubMed Central  Google Scholar 

Uzkeser H, Karatay S, Erdemci B, Koc M, Senel K. Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial. Breast Cancer (Tokyo, Japan). 2015;22(3):300–7. https://doi.org/10.1007/s12282-013-0481-3.

Article  PubMed  Google Scholar 

Keith L, Rowsemitt C, Richards LG. Lifestyle modification group for lymphedema and obesity results in significant health outcomes. Am J Lifestyle Med. 2020;14(4):420–8. https://doi.org/10.1177/1559827617742108.

Article  PubMed  Google Scholar 

Schmitz KH, Troxel AB, Dean LT, et al. Effect of home-based exercise and weight loss programs on breast cancer-related lymphedema outcomes among overweight breast cancer survivors: the WISER survivor randomized clinical trial. JAMA Oncol. 2019;5(11):1605–13. https://doi.org/10.1001/jamaoncol.2019.2109.

Article  PubMed  PubMed Central  Google Scholar 

Kayıran O, De La Cruz C, Tane K, Soran A. Lymphedema: from diagnosis to treatment. Turk J Surg. 2017;33(2):51–7. https://doi.org/10.5152/turkjsurg.2017.3870.

Article  PubMed  PubMed Central  Google Scholar 

Carl HM, Walia G, Bello R, et al. Systematic review of the surgical treatment of extremity lymphedema. J Reconstr Microsurg. 2017;33(6):412–25. https://doi.org/10.1055/s-0037-1599100.

Article  PubMed  Google Scholar 

Forte AJ, Boczar D, Huayllani MT, Lu X, McLaughlin SA. Pharmacotherapy agents in lymphedema treatment: a systematic review. Cureus. 2019;11(12):e6300. https://doi.org/10.7759/cureus.6300.

Article  PubMed  PubMed Central  Google Scholar 

Walker J, Tanna S, Roake J, Lyons O. A systematic review of pharmacologic and cell-based therapies for treatment of lymphedema (2010–2021). J Vasc Surg Venous Lymphatic Disord. 2021. https://doi.org/10.1016/j.jvsv.2021.09.004.

Badger C, Seers K, Preston N, Mortimer P. Antibiotics / anti-inflammatories for reducing acute inflammatory episodes in lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;2:Cd003143. https://doi.org/10.1002/14651858.CD003143.pub2.

Article  Google Scholar 

Forte AJ, Boczar D, Huayllani MT, McLaughlin SA, Bagaria S. Topical approach to delivering targeted therapies in lymphedema treatment: a systematic review. Cureus. 2019;11(12):e6269. https://doi.org/10.7759/cureus.6269.

Article  PubMed  PubMed Central  Google Scholar 

Forte AJ, Boczar D, Huayllani MT, McLaughlin SA, Bagaria S. Use of gene transfer vectors in lymphedema treatment: a systematic review. Cureus. 2019;11(10):e5887. https://doi.org/10.7759/cureus.5887.

Article  PubMed  PubMed Central  Google Scholar 

Forte AJ, Boczar D, Huayllani MT, Cinotto GJ, McLaughlin S. Targeted therapies in surgical treatment of lymphedema: a systematic review. Cureus. 2019;11(8):e5397. https://doi.org/10.7759/cureus.5397.

Article  PubMed  PubMed Central  Google Scholar 

Secker GA, Harvey NL. Regulation of VEGFR signalling in lymphatic vascular development and disease: an update. Int J Mol Sci. 2021;22(14). https://doi.org/10.3390/ijms22147760.

Lahdenranta J, Hagendoorn J, Padera TP, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Can Res. 2009;69(7):2801–8. https://doi.org/10.1158/0008-5472.Can-08-4051.

Article  CAS  Google Scholar 

Mäkinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7(2):199–205. https://doi.org/10.1038/84651.

Article  PubMed  Google Scholar 

Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97(1):14–21. https://doi.org/10.1093/jnci/dji003.

Article  CAS  PubMed  Google Scholar 

Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20(6):1223–31. https://doi.org/10.1093/emboj/20.6.1223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh SJ, Jeltsch MM, Birkenhäger R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997;188(1):96–109. https://doi.org/10.1006/dbio.1997.8639.

Article  CAS  PubMed  Google Scholar 

Mäkinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20(17):4762–73. https://doi.org/10.1093/emboj/20.17.4762.

Article  PubMed  PubMed Central  Google Scholar 

Zarkada G, Heinolainen K, Makinen T, Kubota Y, Alitalo K. VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Proc Natl Acad Sci USA. 2015;112(3):761–6. https://doi.org/10.1073/pnas.1423278112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA. 2001;98(22):12677–82. https://doi.org/10.1073/pnas.221449198.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szuba A, Skobe M, Karkkainen MJ, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16(14):1985–7. https://doi.org/10.1096/fj.02-0401fje.

Article  CAS  PubMed  Google Scholar 

Cheung L, Han J, Beilhack A, et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs. 2006;20(6):363–70. https://doi.org/10.2165/00063030-200620060-00007.

Article  PubMed  Google Scholar 

Jin DP, An A, Liu J, Nakamura K, Rockson SG. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. Lymphat Res Biol. 2009;7(1):47–57. https://doi.org/10.1089/lrb.2009.0002.

Article 

Comments (0)

No login
gif